LSV Asset Management Trims Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

LSV Asset Management lowered its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 13.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 390,451 shares of the specialty pharmaceutical company's stock after selling 60,800 shares during the quarter. LSV Asset Management owned about 1.21% of Collegium Pharmaceutical worth $11,186,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Invesco Ltd. boosted its stake in Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after acquiring an additional 289,335 shares in the last quarter. Principal Financial Group Inc. increased its position in Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock worth $67,459,000 after buying an additional 64,958 shares during the period. Renaissance Technologies LLC lifted its stake in Collegium Pharmaceutical by 0.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company's stock valued at $47,603,000 after buying an additional 5,480 shares during the last quarter. Geode Capital Management LLC lifted its stake in Collegium Pharmaceutical by 0.7% in the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock valued at $29,974,000 after buying an additional 5,464 shares during the last quarter. Finally, Royce & Associates LP boosted its holdings in shares of Collegium Pharmaceutical by 11.0% in the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company's stock valued at $9,728,000 after acquiring an additional 33,674 shares during the period.

Remove Ads

Analysts Set New Price Targets

A number of brokerages have recently commented on COLL. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. StockNews.com upgraded shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday. Needham & Company LLC reiterated a "buy" rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Finally, Piper Sandler dropped their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $43.60.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 10,445 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares in the company, valued at $4,959,032.46. This represents a 5.95 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Scott Dreyer sold 2,255 shares of the company's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares in the company, valued at $3,732,630. This trade represents a 1.78 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,693 shares of company stock valued at $2,334,994. 3.98% of the stock is owned by company insiders.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL traded up $0.39 during trading hours on Tuesday, hitting $27.12. 358,999 shares of the stock were exchanged, compared to its average volume of 443,989. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company has a market cap of $871.42 million, a price-to-earnings ratio of 11.69 and a beta of 0.76. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $42.29. The stock has a 50-day moving average of $28.98 and a 200 day moving average of $31.44.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. As a group, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.